These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 12780556)
1. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Jordan S; Cunningham-Rundles C; McEwan R Am J Transplant; 2003 Jun; 3(6):653-64. PubMed ID: 12780556 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. Jordan SC; Tyan D; Stablein D; McIntosh M; Rose S; Vo A; Toyoda M; Davis C; Shapiro R; Adey D; Milliner D; Graff R; Steiner R; Ciancio G; Sahney S; Light J J Am Soc Nephrol; 2004 Dec; 15(12):3256-62. PubMed ID: 15579530 [TBL] [Abstract][Full Text] [Related]
3. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Vo AA; Peng A; Toyoda M; Kahwaji J; Cao K; Lai CH; Reinsmoen NL; Villicana R; Jordan SC Transplantation; 2010 May; 89(9):1095-102. PubMed ID: 20110854 [TBL] [Abstract][Full Text] [Related]
4. Differential inhibitory effects of intravenous immunoglobulin preparations on HLA-alloantibodies in vitro. Wassmuth R; Hauser IA; Schuler K; Erxleben H; Arnold ML; Koelman CA; Claas FH; Kalden JR Transplantation; 2001 May; 71(10):1436-42. PubMed ID: 11391232 [TBL] [Abstract][Full Text] [Related]
5. Use of high-dose human immune globulin in highly sensitized patients on the kidney transplant waiting list: one center's experience. Gozdowska J; Urbanowicz A; Perkowska-Ptasinska A; Michalska K; Chmura A; Szmidt J; Durlik M Transplant Proc; 2009 Oct; 41(8):2997-3001. PubMed ID: 19857660 [TBL] [Abstract][Full Text] [Related]
6. Intravenous human immunoglobulin treatment of serum from HLA-sensitized patients in kidney transplantation. Picascia A; Grimaldi V; Paolillo R; Vasco M; Casamassimi A; De Luca FP; Cavalca F; Schiano C; Napoli C Ren Fail; 2014 May; 36(4):585-8. PubMed ID: 24456257 [TBL] [Abstract][Full Text] [Related]
7. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience. Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614 [TBL] [Abstract][Full Text] [Related]
8. [Intravenous polyclonal immunoglobulins (IVIG): what use in transplantation?]. Haymann JP; Glotz D Nephrologie; 1999; 20(3):139-43. PubMed ID: 10418003 [TBL] [Abstract][Full Text] [Related]
9. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients. Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R Clin Transpl; 2014; ():215-21. PubMed ID: 26281148 [TBL] [Abstract][Full Text] [Related]
10. Anti-HLA antibody repertoire after IVIg infusion in highly sensitized patients waiting for kidney transplantation. Ferrari-Lacraz S; Aubert V; Buhler L; Pascual M; Andresen I; Binet I; Martin PY; Villard J Swiss Med Wkly; 2006 Oct; 136(43-44):696-702. PubMed ID: 17183432 [TBL] [Abstract][Full Text] [Related]
13. Desensitizing the broadly human leukocyte antigen-sensitized patient awaiting deceased donor kidney transplantation. Jordan SC; Reinsmoen N; Lai CH; Cao K; Kahwaji J; Peng A; Villicana R; Vo A Transplant Proc; 2012 Jan; 44(1):60-1. PubMed ID: 22310579 [TBL] [Abstract][Full Text] [Related]
14. Rituximab and intravenous immune globulin for desensitization during renal transplantation. Vo AA; Lukovsky M; Toyoda M; Wang J; Reinsmoen NL; Lai CH; Peng A; Villicana R; Jordan SC N Engl J Med; 2008 Jul; 359(3):242-51. PubMed ID: 18635429 [TBL] [Abstract][Full Text] [Related]
15. Phenotypic and Transcriptomic Lymphocytes Changes in Allograft Recipients After Intravenous Immunoglobulin Therapy in Kidney Transplant Recipients. Pilon C; Bigot J; Grondin C; Thiolat A; Lang P; Cohen JL; Grimbert P; Matignon M Front Immunol; 2020; 11():34. PubMed ID: 32038663 [TBL] [Abstract][Full Text] [Related]
16. Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Jordan SC; Vo AA; Peng A; Toyoda M; Tyan D Am J Transplant; 2006 Mar; 6(3):459-66. PubMed ID: 16468954 [TBL] [Abstract][Full Text] [Related]
17. Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients. Jordan SC; Toyoda M; Kahwaji J; Vo AA Am J Transplant; 2011 Feb; 11(2):196-202. PubMed ID: 21219579 [TBL] [Abstract][Full Text] [Related]
18. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. John R; Lietz K; Burke E; Ankersmit J; Mancini D; Suciu-Foca N; Edwards N; Rose E; Oz M; Itescu S Circulation; 1999 Nov; 100(19 Suppl):II229-35. PubMed ID: 10567309 [TBL] [Abstract][Full Text] [Related]